{"entity":{"type":"insider","cik":"0001459450","url":"/insider/0001459450","json_url":"/insider/0001459450.json","name":"Myrexis, Inc.","name_source":"as-filed","also_issuer":true,"cross_url":"/issuer/0001459450"},"coverage_statement":{"n_transactions":9,"n_filings":4,"first":"2020-03-31","last":"2021-08-17","span_basis":"filed_date"},"name_variants":[{"name":"Myrexis, Inc.","source":"filing","n_filings":4,"first_seen":"2020-03-31","last_seen":"2021-08-17"}],"transactions":[{"id":5492582,"accession":"0000921895-21-002138","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-21-002138","line_url":"/filing/0000921895-21-002138","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"Myrexis, Inc.; COUCHMAN JONATHAN; Xstelos Corp.; Couchman Family Fund","owner_display_name":"Myrexis, Inc.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":107500.0,"shares_display":"107,500","price_per_share":0.3898,"price_display":"0.39","price_state":"stated","total_value":41903.5,"total_display":"41,903.50","total_whole":"41,904","shares_owned_after":2043024.0,"shares_owned_after_display":"2,043,024","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-08-13","filed_date":"2021-08-17","scope":"insider","n_lines":2},{"id":2386303,"accession":"0000921895-20-002331","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-20-002331","line_url":"/filing/0000921895-20-002331#line-2","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"HARPER ASSET MANAGEMENT LLC; Myrexis, Inc.; Couchman Family Fund; Xstelos Corp.; Pearce Michael Cooper; Harper Brian James; COUCHMAN JONATHAN","owner_display_name":"HARPER ASSET MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":25000.0,"shares_display":"25,000","price_per_share":0.1913,"price_display":"0.19","price_state":"stated","total_value":4782.5,"total_display":"4,782.50","total_whole":"4,783","shares_owned_after":1590194.0,"shares_owned_after_display":"1,590,194","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-25","filed_date":"2020-08-26","scope":"insider"},{"id":2386298,"accession":"0000921895-20-002331","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-20-002331","line_url":"/filing/0000921895-20-002331#line-1","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"HARPER ASSET MANAGEMENT LLC; Myrexis, Inc.; Couchman Family Fund; Xstelos Corp.; Pearce Michael Cooper; Harper Brian James; COUCHMAN JONATHAN","owner_display_name":"HARPER ASSET MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":52100.0,"shares_display":"52,100","price_per_share":0.1834,"price_display":"0.18","price_state":"stated","total_value":9555.14,"total_display":"9,555.14","total_whole":"9,555","shares_owned_after":1615194.0,"shares_owned_after_display":"1,615,194","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-24","filed_date":"2020-08-26","scope":"insider"},{"id":2134898,"accession":"0000921895-20-002115","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-20-002115","line_url":"/filing/0000921895-20-002115#line-1","is_derivative":false,"issuer_cik":"0000727510","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0000727510","owner_cik":null,"owner_name":"HARPER ASSET MANAGEMENT LLC; Myrexis, Inc.; Couchman Family Fund; Xstelos Corp.; Pearce Michael Cooper; Harper Brian James; COUCHMAN JONATHAN","owner_display_name":"HARPER ASSET MANAGEMENT LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":506292.0,"shares_display":"506,292","price_per_share":0.2,"price_display":"0.20","price_state":"stated","total_value":101258.4,"total_display":"101,258.40","total_whole":"101,258","shares_owned_after":2100524.0,"shares_owned_after_display":"2,100,524","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-08-05","filed_date":"2020-08-06","scope":"insider"},{"id":9208948,"accession":"0000921895-20-000958","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-20-000958","line_url":"/filing/0000921895-20-000958#line-4","is_derivative":false,"issuer_cik":"0001265094","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0001265094","owner_cik":null,"owner_name":"COUCHMAN JONATHAN; Couchman Family Fund; Myrexis, Inc.; Xstelos Corp.","owner_display_name":"COUCHMAN JONATHAN","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":160785.0,"shares_display":"160,785","price_per_share":0.14,"price_display":"0.14","price_state":"stated","total_value":22509.9,"total_display":"22,509.90","total_whole":"22,510","shares_owned_after":633264.0,"shares_owned_after_display":"633,264","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-26","filed_date":"2020-03-31","scope":"insider"},{"id":9208949,"accession":"0000921895-20-000958","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000921895-20-000958","line_url":"/filing/0000921895-20-000958#line-3","is_derivative":false,"issuer_cik":"0001265094","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0001265094","owner_cik":null,"owner_name":"COUCHMAN JONATHAN; Couchman Family Fund; Myrexis, Inc.; Xstelos Corp.","owner_display_name":"COUCHMAN JONATHAN","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":469551.0,"shares_display":"469,551","price_per_share":0.14,"price_display":"0.14","price_state":"stated","total_value":65737.14,"total_display":"65,737.14","total_whole":"65,737","shares_owned_after":472479.0,"shares_owned_after_display":"472,479","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-25","filed_date":"2020-03-31","scope":"insider"},{"id":9208950,"accession":"0000921895-20-000958","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000921895-20-000958","line_url":"/filing/0000921895-20-000958#line-2","is_derivative":false,"issuer_cik":"0001265094","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0001265094","owner_cik":null,"owner_name":"COUCHMAN JONATHAN; Couchman Family Fund; Myrexis, Inc.; Xstelos Corp.","owner_display_name":"COUCHMAN JONATHAN","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2678.0,"shares_display":"2,678","price_per_share":0.14,"price_display":"0.14","price_state":"stated","total_value":374.92,"total_display":"374.92","total_whole":"375","shares_owned_after":2928.0,"shares_owned_after_display":"2,928","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-23","filed_date":"2020-03-31","scope":"insider"},{"id":9208947,"accession":"0000921895-20-000958","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000921895-20-000958","line_url":"/filing/0000921895-20-000958#line-1","is_derivative":false,"issuer_cik":"0001265094","issuer_name":"ENZON PHARMACEUTICALS, INC.","issuer_ticker":"ENZN","issuer_name_source":null,"issuer_url":"/issuer/0001265094","owner_cik":null,"owner_name":"COUCHMAN JONATHAN; Couchman Family Fund; Myrexis, Inc.; Xstelos Corp.","owner_display_name":"COUCHMAN JONATHAN","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock, $0.01 par value","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":19709.0,"shares_display":"19,709","price_per_share":0.135,"price_display":"0.14","price_state":"stated","total_value":2660.715,"total_display":"2,660.72","total_whole":"2,661","shares_owned_after":1594232.0,"shares_owned_after_display":"1,594,232","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-13","filed_date":"2020-03-31","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0000727510","name":"ENZON PHARMACEUTICALS, INC.","url":"/issuer/0000727510","role":"Ten percent owner, Other","n_filings":4,"first_seen":"2020-03-31","last_seen":"2021-08-17"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001459450","retrieved_at":"2026-08-26T01:00:00+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-24","last_ingest":"2026-08-25T05:24:19.374141+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}